MAP Pharmaceuticals LLC
(NASDAQ : MAPP)

( )
MAPP PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
TMOThermo Fisher Scientific, Inc. -1.14%548.861.0%$904.15m
DHRDanaher Corp. -0.38%252.160.7%$718.28m
ABTAbbott Laboratories -1.01%113.870.8%$652.99m
ISRGIntuitive Surgical, Inc. -1.45%218.390.8%$517.56m
MDTMedtronic Plc 1.29%105.600.6%$491.01m
BSXBoston Scientific Corp. 0.63%40.141.0%$397.53m
ALGNAlign Technology, Inc. -3.06%270.186.4%$372.96m
SYKStryker Corp. 0.29%233.721.3%$354.68m
IDXXIDEXX Laboratories, Inc. -1.68%362.163.8%$340.47m
BDXBecton, Dickinson & Co. 0.23%257.601.0%$319.47m
EWEdwards Lifesciences Corp. -1.72%94.480.4%$301.32m
DXCMDexCom, Inc. -11.05%288.137.7%$275.83m
AAgilent Technologies, Inc. -0.99%124.731.6%$264.35m
BAXBaxter International, Inc. 0.83%73.981.8%$241.38m
MTDMettler-Toledo International, Inc. -1.25%1231.915.8%$193.85m

Company Profile

MAP Pharmaceuticals, Inc., a development stage company, focuses on developing novel inhalation therapies for respiratory and systemic diseases. It has various proprietary product candidates in clinical development, including Unit Dose Budesonide for pediatric asthma in children from six months to eight years of age and MAP0004 for migraine. The company's product portfolio also includes MAP0005 for the treatment of adolescent and adult asthma, and chronic obstructive pulmonary disease; and MAP0001 for the treatment of Type 1 and Type 2 diabetes via pulmonary delivery using its Tempo inhaler. MAP Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Mountain View, California.